To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open271.95
High271.95
Low261.05
Prev. Close263.3
Avg. Traded Price266.41
Volume48,545

MARKET DEPTH

info2
Total bid0.00
Total ask701.00
OrdersQtyBid
000
000
000
000
000
AskQtyOrders
263.31701
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

261.0510 hours ago
271.9516 hours ago
arrow

LOWER/UPPER CIRCUITS

254.20
280.90
arrow
Dishman Carbogen Amcis Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 3.37%, in the last year to ₹2,733.18 Cr. Its sector's average revenue growth for the last fiscal year was 10.53%.
noteAnnual Net Profit,rose 102.11% in the last year to ₹3.24 Cr. Its sector's average net profit growth for the last fiscal year was 37.23%.
notePrice to Earning Ratio,is 40.25, lower than its sector PE ratio of 41.5.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 2.48%
Net profit growth 5Y CAGR : %
Dishman Carbogen Amcis Limited (DCAL), incorporated in 1983, started out as a manufacturer of quaternary ammonium and phosphate compounds. Currently, the company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.
personal

Grow your wealth with more research recommendations

+91